作者: Reno Debets , Emmanuel Donnadieu , Salem Chouaib , George Coukos
DOI: 10.1016/J.SMIM.2016.03.002
关键词:
摘要: Adoptive transfer of T cells gene-engineered with cell receptors (TCRs) has proven its feasibility and therapeutic potential in the treatment malignant tumors. To ensure further clinical development TCR gene therapy, it is necessary to accurately select TCRs that demonstrate antigen-selective responses are restricted tumor and, at same time, include strategies restore or enhance entry, migration local accumulation tissues. Here, we present current standing TCR-engineered discuss propose procedures as well sensitize trafficking, provide a rationale for combination therapies cells.